By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed.
Moonwalk is the first company to couple an epigenetic discovery platform with precise engineering – opening up the epigenome as a new target space for complex diseases.
Moonwalk technology brings the most advanced AI prediction of epigenetic targets, and the broadest set of epigenetic engineering tools.
Moonwalk’s focus on epigenetic engineering leverages comprehensive read-and-write technologies to develop potentially curative therapies for diseases at the root cause.
Matt Kaeberlein, PhD
CEO at Optispan, Inc., and Affiliate Professor of Oral Health Sciences, University of Washington
Ed Scolnick, MD
Former President of Merck Research Laboratories; Core Broad Institute Member and Chief Scientist Emeritus